Cargando…

Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration

Candesartan Cilexetil (CC) is a prodrug widely used in the treatment of hypertension and heart failure, but it has some limitations, such as very poor aqueous solubility, high affinity to P-glycoprotein efflux mechanism, and hepatic first-pass metabolism. Therefore, it has very low oral bioavailabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anwar, Walid, Dawaba, Hamdy M., Afouna, Mohsen I., Samy, Ahmed M., Rashed, Mohammed H., Abdelaziz, Abdelaziz E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692391/ https://www.ncbi.nlm.nih.gov/pubmed/33142816 http://dx.doi.org/10.3390/pharmaceutics12111047

Ejemplares similares

Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug
por: Aly, Usama Farghaly, et al.
Publicado: (2020)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
por: Mady, Omar Y., et al.
Publicado: (2021)

Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)

Candesartan cilexetil: COVID-19 pneumonia: case report
Publicado: (2020)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
por: Xu, Lanlan, et al.
Publicado: (2021)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011)

Design and development and evaluation of candesartan cilexetil liquid filling formulations
por: Deepthi, Y., et al.
Publicado: (2015)

Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
por: Sravya, Maddukuri, et al.
Publicado: (2013)

New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats
por: AbuElfadl, Aya, et al.
Publicado: (2021)

The Effect of Polysorbate 20 on Solubility and Stability of Candesartan Cilexetil in Dissolution Media
por: Hoppe, Katarzyna, et al.
Publicado: (2014)

Chemometric Methods for Simultaneous Determination of Candesartan Cilexetil and Hydrochlorothiazide in Binary Combinations
por: Ali, Diyar Salahuddin
Publicado: (2023)

Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study
por: Detroja, Chetan, et al.
Publicado: (2011)

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study
por: Baguet, JP, et al.
Publicado: (2009)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
por: Figueroa-Campos, Andrés, et al.
Publicado: (2020)

Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion
por: Kamalakkannan, V, et al.
Publicado: (2013)

Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers
por: Murthy, Aditya, et al.
Publicado: (2020)

Improving intestinal absorption and oral bioavailability of curcumin via taurocholic acid-modified nanostructured lipid carriers
por: Tian, Cihui, et al.
Publicado: (2017)

EGCG intestinal absorption and oral bioavailability enhancement using folic acid-functionalized nanostructured lipid carriers
por: Granja, Andreia, et al.
Publicado: (2019)

Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
por: Mengden, Thomas, et al.
Publicado: (2009)

Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions
por: Tjandrawinata, Raymond R, et al.
Publicado: (2013)

Nephroprotective effects of Candesartan Cilexetil against Cyclosporine A-induced nephrotoxicity in a rat model
por: Ghafil, Fadhaa Abdulameer, et al.
Publicado: (2022)

Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers
por: Zhou, Jun, et al.
Publicado: (2015)

The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia
por: Quinlan, Sean, et al.
Publicado: (2019)

New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets
por: Belal, Tarek S., et al.
Publicado: (2013)

Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs
por: Khan, Saba, et al.
Publicado: (2015)

Augmented Oral Bioavailability and Prokinetic Activity of Levosulpiride Delivered in Nanostructured Lipid Carriers
por: Arif, Sadia Tabassam, et al.
Publicado: (2022)

Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance
por: Poudel, Surendra, et al.
Publicado: (2021)

Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials
por: Féghali, Ramzi EL, et al.
Publicado: (2007)

A validated ultra high-pressure liquid chromatography method for separation of candesartan cilexetil impurities and its degradents in drug product
por: Kumar, Namala Durga Atchuta, et al.
Publicado: (2012)

Enhancing Oral Bioavailability and Brain Biodistribution of Perillyl Alcohol Using Nanostructured Lipid Carriers
por: Peczek, Samila Horst, et al.
Publicado: (2023)

Tailoring Apixaban in Nanostructured Lipid Carrier Enhancing Its Oral Bioavailability and Anticoagulant Activity
por: Zaky, Mohamed F., et al.
Publicado: (2022)

Application of Optimization Technique to Develop Nano-Based Carrier of Nigella sativa Essential Oil: Characterization and Assessment
por: Dawaba, Aya M., et al.
Publicado: (2019)

Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model
por: YAN, WEN-HUA, et al.
Publicado: (2016)

Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction
por: Chang, Gwo‐Jyh, et al.
Publicado: (2022)

Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer’s patch targeting approach
por: Prajapati, Jagruti B, et al.
Publicado: (2018)

Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine
por: Chen, Yan, et al.
Publicado: (2012)

Pharmacokinetics and bioequivalence of fixed-dose combination of candesartan cilexetil/amlodipine besylate (16/10 mg) versus coadministration of individual formulations in healthy subjects
por: Lee, Hae Won, et al.
Publicado: (2020)

No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2018)

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study
por: Rakugi, Hiromi, et al.
Publicado: (2012)

Nanostructured Lipid Carriers Can Enhance Oral Absorption of Khellin, a Natural Pleiotropic Molecule
por: Vanti, Giulia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ili8dlr3egbnldjv8hu4uvmajs